Arbutus Biopharma (ABUS) said Wednesday that it has reacquired rights to its lead compound, imdusiran, in Greater China from Qilu Pharmaceutical.

Arbutus said the parties have mutually agreed to end their partnership, which began in 2021, to develop, manufacture and commercialize imdusiran in mainland China and other Asian markets.